According to the Zhitong Finance App, Eagle Hitomi Technology-B (02251) announced that the Group expects to achieve a net loss of no more than RMB 50 million in the mid-term of 2026, while the Group will earn a net profit of approximately RMB 440,000 during the same period in 2025. This change is mainly due to the following factors: (i) increased investment in R&D and clinical trials: increased investment in R&D, computing power, and medical data governance of AI agents in various product lines, promoted multi-center clinical, device registration and compliance commercialization, and increased R&D and clinical expenses; (ii) the PBM-AI myopia prevention and control business is in a period of expansion and cultivation: the number of partner stores, users and model calls increased; market, medical services, store deployment, operation, and C-eye health marketing operations have not contributed to the increase in the volume of revenue contributions and scale of this business line release; and ( iii) Exchange rate changes also have a certain impact on the Group's financial position. Therefore, the Group adjusted its organizational structure, empowered the middle and back office with the help of the “Ten Thousand Languages” model, and increased cost efficiency, thereby partially offsetting the above pressure.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.